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Abstract
Background: Whether for cell culture studies of protein function, construction of mouse models
to enable in vivo analysis of disease epidemiology, or ultimately gene therapy of human diseases, a
critical enabling step is the ability to achieve finely controlled regulation of gene expression.
Previous efforts to achieve this goal have explored inducible drug regulation of gene expression,
and construction of synthetic promoters based on two-hybrid paradigms, among others.
Results:  In this report, we describe the combination of dimerizer-regulated two-hybrid and
tetracycline regulatory elements in an ordered cascade, placing expression of endpoint reporters
under the control of two distinct drugs. In this Dual Drug Control (DDC) system, a first plasmid
expresses fusion proteins to DBD and AD, which interact only in the presence of a small molecule
dimerizer; a second plasmid encodes a cassette transcriptionally responsive to the first DBD,
directing expression of the Tet-OFF protein; and a third plasmid encodes a reporter gene
transcriptionally responsive to binding by Tet-OFF. We evaluate the dynamic range and specificity
of this system in comparison to other available systems.
Conclusion: This study demonstrates the feasibility of combining two discrete drug-regulated
expression systems in a temporally sequential cascade, without loss of dynamic range of signal
induction. The efficient layering of control levels allowed by this combination of elements provides
the potential for the generation of complex control circuitry that may advance ability to regulate
gene expression in vivo.
Background
To achieve effective control of gene expression in vivo,
higher eukaryotes generally utilize extensive promoter/
enhancer/locus control regions spanning many kilobases
of DNA, and encompass multiple discrete binding sites
for transcription factors that combinatorially encode spe-
cificity of gene transcription. However, for studies of gene
function requiring the introduction of heterologous pro-
tein into cultured cells, there is a practical limit governing
the size of promoter that can be utilized, corresponding to
the 2–3 kb of enhancer/promoter sequence that can be
accommodated on a plasmid that also must contain other
required sequence elements. Currently, many of the gene
expression systems commonly utilized for studies of
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protein function utilize small, virally derived enhancers
(for example, from cytomegalovirus, CMV) that typically
do not provide many options for calibrating the expres-
sion of encoded proteins, but rather produce constitutive
high levels of protein product following introduction into
cells. Although some inducible gene expression systems
have been developed using natural promoter elements,
disadvantages of these systems prevented them from gain-
ing broad use. As one example, although use of the metal-
lothionein promoter [1] allows induction of gene
expression through addition of metals to cell culture, the
attendant cellular stress response arising from exposure to
metals can cause secondary effects complicating the inter-
pretation of resulting data.
As an alternative approach, a number of groups have
explored the possibilities of developing small artificial
promoters or transcriptional regulatory systems with
desirable properties for gene expression control. It has
long been appreciated that it is possible to generate novel
transcriptional control systems by fusing separable DNA
binding domains (DBDs) and transcriptional activation
domains (ADs) to achieve a desired transcriptional activa-
tion specificity [2]. The fact that it is possible to create
functional transcriptional regulatory control systems even
in situations where the DBD and AD are not covalently
attached is the guiding principle behind technologies
such as the yeast two hybrid system [3]. In adapting these
concepts to the design of artificial gene expression sys-
tems, previous work by some groups has demonstrated
the possibility of constructing elegant combinatorial sys-
tems incorporating feedback loops, based on the integra-
tion of two-hybrid system paradigms with diverse tissue
specific promoters (e.g. [4-6]). Separately, others have
shown the efficient regulation of gene expression through
artificial promoters dependent on the action of small mol-
ecule modulators, including tetracycline and derivatives
(reviewed in [7]); streptogramin and macrolide antibiot-
ics, [8-10]; combined coumermycin and novobiocin sys-
tems [11]; ecdysone [12]; dimerizer molecules such as
FK1012 and other rapamycin-related derivatives [13,14].
Further afield, derivatives of the "quorum-sensing" cir-
cuits of bacteria, that assess cell density to regulate inter-
conversion between biofilms and other growth forms
[15], and components of the plant phytochrome system,
in which promoter activity can be regulated by light [16],
have been adapted for artificial promoter construction.
Each of these systems offers specific advantages for some
applications. Notably, in order to generate flexible tools
for general usage in achieving fine control of gene expres-
sion, it would be useful to be able to combine elements of
these different systems. However, it has not to date been
clear whether these artificial transcriptional regulatory
reagents are sufficiently robust to be merged into more
complex regulatory cascades, particularly under the condi-
tions of transient transfection generally preferred for rapid
experimentation. This is potentially a non-trivial prob-
lem, as in increasing the number of cascade elements,
more control points are introduced that might contribute
to loss of efficiency, specificity, or dynamic range. Never-
theless, sequential cascades combining different groups of
transcription factors, with localization and activity regu-
lated by multiple inputs from modifying factors such as
kinases, phosphatases, acetylases, and other enzymes rep-
resents a standard means of gene regulation in naturally
occurring living organisms. It is likely that the complexity
arising from the multiple inputs leads to more fine-tuning
of output, and enables a more complex biological
response. Our goals in undertaking the present study were
two-fold: first, to evaluate the results of arraying two dis-
crete, artificial transcriptional control systems in contrast
to the results obtained with each system in isolation; and
second, optimally, to develop a reagent system that is
practically useful in achieving more fine control of gene
expression.
In this report we combine a set of elements developed by
various research groups with new elements constructed
herein to create a complex multi-component system
intended for use in transient experiments. In this system,
a first plasmid expresses fusion proteins to DBD and AD,
which interact contingent on the presence of a small mol-
ecule dimerizer; a second plasmid encodes a cassette tran-
scriptionally responsive to the first DBD, directing
expression of the Tet-OFF protein; and a third plasmid
encodes a reporter gene transcriptionally responsive to
binding by Tet-OFF. In a series of tests, we evaluate the
dynamic range and specificity of this Dual Drug Control
(DDC) system in contrast to simpler systems, and note
issues of particular importance for future tool develop-
ment. Finally, we discuss several potential applications for
a DDC system.
Results and discussion
To judge the potential for development of sequential
drug-regulated signaling cascades using artificial compo-
nents in mammalian cells, we established the following
multi-component DDC system (Figure 1). A first plasmid,
(pC4N2-RHS/ZF3) previously developed by Rivera et al.
[17] uses a CMV promoter and an internal ribosomal
entry site (IRES) to co-express a DBD (derived from the
homeodomain protein ZFHD1, [18]) fused to three tan-
demly repeated copies of human rapamycin-binding pro-
tein FKBP12, and an AD (derived from the p65 processed
peptide of the NF-κB transcription factor) fused to a sec-
ond rapamycin-binding protein, FRAP. These two pro-
teins interact solely in the presence of small non-
immunosuppressive rapamycin-related dimerizers, such
as AP21967 [19]. A second plasmid (pZBS-Tet-OFF, forBMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/9
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A. Schematic of system Figure 1
A. Schematic of system. DBD (ZFHD) and AD (p65) fused components are co-expressed either as a single unit from one 
CMV promoter using an IRES element, or are separated to two different plasmids (DBD from pAr-DBD and AD from pAr-
AD). In the presence of dimerizer, these elements activate expression of a ZFHD-responsive reporter (hGH or SEAP) and the 
tTA protein. In the absence of tetracycline, tTA activates expression of gene 2 (SEAP or GFP).BMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/9
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ZFHD Binding Site) contains a binding site for ZFHD-
fused activators to direct transcription of the tTA gene,
encoding a protein that activates transcription only in the
absence of bound tetracycline [20]. Finally, a third plas-
mid (pBI-EGFP-SEAP) contains a binding site for tTA
upstream of the SEAP gene, providing a final readout for
regulation of the upstream regulatory modules.
Our first goal was to determine whether this artificial tran-
scriptional cascade worked in a transient mode, and if so,
to optimize the dynamic range of gene expression. We
therefore performed a titration experiment in which we
systematically varied the relative ratios of the three com-
ponent plasmids transiently transfected into cells (Figure
2A). For this experiment, SEAP levels were assessed after
incubation under conditions in which the reagents were
predicted to be operative (with the AP21967 dimerizer,
lacking tetracycline), and compared to SEAP levels under
non-operative conditions (without dimerizer, plus tetra-
cycline). These experiments first demonstrated that a
robust SEAP signal was detectable under conditions of
dual drug induction over a range of plasmid concentra-
tions and allowed to determine the optimal plasmid con-
centrations to achieve a broad dynamic range between the
induced and uninduced conditions (see legend, Figure 2).
Based on this preliminary study, we selected a ratio of
5:3:2 for pC4N2-RHS/ZF3: pZBS-Tet-OFF: pBI-EGFP-SEAP,
respectively.
We then characterized the inductive properties of the opti-
mized DDC system versus the Tet-OFF and dimerizer
parental systems from which it was derived (Figure 3),
using comparable quantities of total plasmid in each case.
In these experiments, treatment of the parental Ariad
dimerizer system with AP21967 (Figure 3, column A)
induced activation of the ZFHD-responsive SEAP reporter
pLH-Z12-I-S over uninduced background by up to ~156-
fold, with this large dynamic range arising in part from the
extremely low background of this system in the unin-
duced state. By contrast, removal of tetracycline from the
medium of cells containing the Tet-Off system (Figure 3,
column B) induced activation of Tet-responsive- SEAP
reporter over uninduced background by ~23-fold. Varying
levels of dimerizer had no effect on the activity of the Tet-
OFF system, and varying levels of tetracycline had no
effect on the activity of the dimerizer system (results not
shown). As shown, the novel DDC system combined the
two requirements specified by the two different parental
systems (Figure 3, column C). Activation of the SEAP
reporter was only observed in the presence of dimerizer,
and in the absence of tetracycline, with all other condi-
tions showing comparable low background. The total
degree of induction observed in a typical experiment was
in the order of 30–40-fold, comparable to previously opti-
mized values. Equivalent levels of induction were
observed in two different cell lines, Cos7 and HeLa.
Importantly, the observed degree of induction with the
new system was comparable to that obtained with use of
the Tet-OFF parental system, and reduced only 3–5-fold
versus the ARIAD system, indicating that neither gain nor
loss of signal strength was observed by the combination of
the two parental systems into a two-tier DDC signaling
systems. In terms of explaining the moderate reduction in
dynamic range versus the ARIAD system, we believe that
this is most simply attributable to the degree of basal tran-
scriptional activity obtained from the Tet-Responsive
Optimization of induction signal Figure 2
Optimization of induction signal. A mixture of 3 plas-
mids (pC4N2-RHS/ZF3, pZBS-Tet-OFF, and pBI-EGFP-SEAP) 
was used for cell transfection; the total amount of plasmid 
DNA was constant at 0.5 µg per test point. As graphically 
represented, at each apex of the triangle shown, only one of 
the test plasmids is present (100% of mix), while opposite the 
matrix this plasmid is absent (0% of mix), with the two other 
plasmids present in equal proportions. White circles indicate 
ratios of plasmids evaluated for degree of induction of SEAP 
activity. Degree of induction reflects difference between 
growth without dimerizer and with tetracycline (OFF), ver-
sus with dimerizer and without tetracycline (ON). Based on 
the ON:OFF ratios obtained, the software program "Statis-
tica" modeled the optimal response surface, shown as a con-
tour plot on the triangle. Faded edges of the triangle 
represent limitations of the model, because it is meaningless 
whenever one of the components is absent. The optimal 
ratio for plasmid transfection with the DDC system was 
1.5:1.5:1 (pC4N2-RHS/ZF3:pZBS-Tet-OFF:pBI-EGFP-SEAP). 
This contrasted with a ratio of 3:1 (activator pro-
teins:reporter) used for the original ARIAD system.BMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/9
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SEAP promoter, as similar total values of SEAP activity
were obtained from DDC and SEAP systems, while
reporter manifested detectable SEAP activity even in the
absence of any additional components (Figure 3, column
D).
We next asked if it were possible to obtain the sequential
activation of different readouts from a single set of plas-
mids, using ordered addition of drugs. By incorporating a
bi-directional promoter at the middle, ZFHD-dependent,
tier of the DDC signaling cascade (see Figure 1), it should
be possible to transfect a single set of plasmids into cells;
induce a first gene and the tTA protein by dimerizer addi-
tion after 1–2 days; then induce a second gene by tetracy-
cline removal. We modeled the feasibility of a two-stage
induction (Figure 4). Four parallel sets of cells (groups A-
D) were transfected with pC4N2-RHS/ZF3 (to co-express
dimerizer-dependent ZFHD- and AD fusion proteins),
pZ12I-hGH-2 (as a ZFHD-dependent reporter), pZBS-Tet-
OFF (for ZFHD-dependent expression of tTA), and pBI-
EGFP-SEAP (for tTA-dependent expression of SEAP).
Group A was grown in dimerizer-/tetracycline+ medium,
while groups B, C, and D were grown in dimerizer+/tetra-
cycline+ medium. After 2 days, groups A and B were proc-
essed for analysis, while groups C and D were grown for 2
more days in dimerizer+/tetracycline+ medium, or
dimerizer+/tetracycline- medium, respectively, before
processing (Figure 4). As shown, as robust induction of
the downstream SEAP component is observed in this two-
stage induction process as was obtained in a simultaneous
induction.
Finally, an advantage of the ARIAD system as developed
by [14] is that the use of an IRES element to express DBD
and AD fusion proteins from a single plasmid, simplifying
transfections. A possible disadvantage of the use of this
otherwise economical system is that it requires the expres-
sion of DBD and AD fusion proteins from the same
enhancer. Some reports have suggested the combination
of two different cell type- or cell cycle-restricted promoters
to express DBD- and AD- fused proteins to target expres-
sion of DBD-dependent reporters to cellular compart-
ments in which both promoters were active (reviewed in
[21]): other means of using two discrete promoters to add
further levels of control to a gene expression system can be
readily imagined. Therefore, we next tested whether the
DDC reporter system behaved comparably under the orig-
inal conditions, in which an IRES element was used to
coordinately express the DBD- and AD- upstream compo-
nents from the CMV promoter (the pC4N2-RHS/ZF3 plas-
mid), versus in a situation in which the expression of
these components were separated to two different plas-
mids (the DBD-FKBP12 protein from pAr-DBD and the
AD-FRAP protein from pAr-AD) each independently
under the control of the CMV promoter. While signal was
still obtained under "split" conditions, the induction over
baseline was very low (data not shown), such that under
the best circumstances the degree of induction of the pLH-
Z12-I-S reporter did not exceed 20–30% that obtained with
the IRES system in three different cell lines (Table 1). The
reduced signal seen with the split system might be due to
promoter competition (between two powerful CMV pro-
moters, rather than one), or due to difficulties in optimiz-
ing plasmid content within cells with 4, rather than 3,
plasmid components. Western analysis indicated similar
expression of AD-FRAP whether expressed from an IRES
or split system (results not shown). Further, generation of
a split system in which one component was expressed
from either the cyclin A promoter [4] or the keratin 17
promoter [22], each of which has been described as work-
ing efficiently in epithelial cell lines, was significantly less
robust in inducing SEAP activity than a split CMV-only
system (results not shown). For these reasons, we believe
the deficiency of a split system reflects difficulty in main-
taining adequate levels and ratios of 4 distinct plasmids
following transfection. Given the degree of induction in a
two-tier system is routinely in the order of 30–40 fold, it
appeared that splitting the two components would result
in too great a reduction of signal intensity to make this
approach feasible, so the use of separated plasmids was
not further pursued.
Conclusions
In summary, this pilot study demonstrates the feasibility
of combining two discrete drug-regulated expression sys-
tems in an ordered cascade. It further demonstrates that
this sequential arrangement of systems does not result in
unworkable reduction in dynamic range of signal induc-
tion, and shows that a comparable level of induction is
obtained using simultaneous or sequential addition of
regulatory drugs. As such, it may prove to be a useful addi-
tion to the toolbox of reagents for control of gene expres-
sion in mammalian cells. Other studies in this area (for
example, the work of Kramer et al., [23]), have also begun
to address the sequential combination of elements
derived from different artificial regulatory systems, with
the goal of "fine-tuning" gene expression. This is likely to
represent an important future theme in promoter design,
and will involve much trial and error of many system
components. Ultimately, it may also provide an informa-
tive model for analysis of elements contributing to effi-
cient propagation of information in signal transduction
cascade, as systems biology evolves as an experimental
science.
Methods
Plasmids
pSEAP2-Enhancer, pRetro-Off, pBI-EGFP, and pEGFP-N1
were acquired from Clontech Labs. pC4N2-RHS/ZF3,
pZ12I-PL-2, pLH-Z12-I-S and pZ12I-hGH-2 were developedBMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/9
Page 6 of 9
(page number not for citation purposes)
Demonstration of dual drug control Figure 3
Demonstration of dual drug control. In Cos7 and HeLa cells, optimized ratios for the parental Ariad dimerizer System 
(A), tTA TET-OFF System (pRetro-OFF) (B), the merged Dual Drug Control (DDC) system (C), and the Tet-SEAP reporter 
in isolation (D) are evaluated for activity in the presence or absence of dimerizer and/or tetracycline. Values shown reflect 
luminometer readings of SEAP reporters. Blue boxes reflect values obtained in Cos7 cells; yellow boxes, in HeLa cells. Stand-
ard deviation is indicated by error bars. Each experiment was repeated at least three times.BMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/9
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Inducing gene expression at two tiers Figure 4
Inducing gene expression at two tiers. Target genes are modeled by the hGH gene (ZFHD-dependent transactivation, 
expression responsive to dimerizer only; scale is on the right Y-axis) and the SEAP gene (tTA-dependent transcription expres-
sion responsive to dimerizer AND tetracycline; scale is on the left Y-axis). All cells contain pC4N2-RHS/ZF3, pZ12I-hGH-2, 
pZBS-Tet-OFF, and pBI-EGFP-SEAP. See Results for details of manipulations A-D; briefly, A was grown in continuous dimer-
izer-/tetracycline+; B-D were initially in dimerizer+/tetracycline+. At 48 hours after transfection with plasmids, A and B were 
harvested, while C and D were grown for 48 more hours in dimerizer+/tetracycline+ (C) or dimerizer+/tetracycline- (D) 
medium before harvesting. Results of one typical experiment, with four parallel transfections for each data point, are shown. 
Each experiment was repeated at least three times.
Table 1: IRES versus split expression of two-hybrid components. Units shown represent fold-induction, induced over uninduced 
conditions, of a ZFHD-dependent SEAP reporter, in three different cell lines.
Cell line CMV/IRES CMV/CMV
Cos7 300 62
HeLa 335 105
A2780 222 11
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
SEAP
hGh
S
E
A
P
h
G
h
ABCD
0
1.0
2.0
3.0
4.0
5.0BMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/9
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by Ariad Pharmaceuticals, and are described in (the
ARGENT Regulated Transcription Plasmid Kit Version 2.0,
Available on-line at http://www.ariad.com/). For this
work, the Renilla luciferase gene (SRUC3) was recloned
from the plasmid pBluescript/SRUC3 [24] to replace the
EGFP gene in pEGFP-N1, creating pSRUC3-N1, a reporter
plasmid with expression of SRUC3 under the control of
the CMV promoter. In pZBS-Tet-OFF, the pRetro-OFF
vector has been modified to place the tTA (tetracycline
repressor fused to viral VP16, [20]) protein under tran-
scriptional control of 12 ZFHD1-binding sites in a mini-
mal promoter context derived from IL2 (from pZ12I-PL-
2). In pBI-EGFP-SEAP, the tetracycline responsive pro-
moter was used to bidirectionally express pEGFP and the
secreted alkaline phosphatase (SEAP) gene. The plasmids
pAR-DBD and pAR-AD were constructed as derivatives of
pC4N2-RHS/ZF3 by eliminating one of the two co-
expressed components initially expressed, such that
ZFHD-FKBP12 (pAR-DBD) or p65-FRAP (pAR-AD) is sep-
arately expressed under the control of the CMV promoter.
Cell culture
Cos7, HeLa, and A2780 cells were used as hosts for trans-
fection experiments, and were cultured using standard
conditions as recommended by the ATCC. Experiments
for optimization of plasmid ratios were planned and ana-
lyzed using the software program STATISTICA http://
www.statsoftinc.com. Transfections were performed using
a TransIT-LT1 reagent from Mirus. The pSRUC3-N1 plas-
mid was transfected together with test combinations of
other plasmids (as described in Results) as a control for
transfection efficiency: typically, 10% of a transfection
mixture would be pSRUC3-N1, and levels of Renilla luci-
ferase assessed in collected medium conditioned by trans-
fected cells, based on standard recommended conditions
[24]. In a standard experiment, transfected cells were
grown in the presence or absence of 25 nM dimerizer
AP21967 (Ariad Pharmaceuticals) and/or in the presence
or absence of 2 µg/ml tetracycline (Sigma). Reporter acti-
vation was determined 42 – 96 hours after transfection.
Comparable expression of p65 activation domain fusion
proteins under induced conditions was confirmed using
polyclonal antibodies directed against NFκB p65 (Geneka
Biotechnology Inc.) in Western analysis.
Reporter assays
Measurement of Renilla luciferase activity and SEAP activ-
ity was performed in a luminometer LKB 1250. Measure-
ment of SEAP activity in culture medium was by standard
means using the chemiluminescent Great EscAPe SEAP
reporter System (Clontech Labs). Renilla luciferase activity
was measured using the Renilla Luciferase Assay System
(Promega). In each case, cells were lysed by incubation for
15 min with Renilla Luciferase Assay Lysis Buffer, and the
lysed samples were cleared by centrifugation for 30 sec at
14000 min-1  in a microcentrifuge. Data presented for
SEAP were corrected based on the calculated transfection
efficiency. Human growth hormone levels were assayed
using an ELISA kit from Roche (# 1 585 878).
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